BENDAMUSTINE Drug Patent Profile
✉ Email this page to a colleague
When do Bendamustine patents expire, and what generic alternatives are available?
Bendamustine is a drug marketed by Accord Hlthcare, Apotex, Breckenridge, Dr Reddys, Eugia Pharma, Meitheal, Nang Kuang Pharm Co, Pharmobedient, Avyxa Holdings, Baxter Hlthcare Corp, and Hospira. and is included in twelve NDAs.
The generic ingredient in BENDAMUSTINE is bendamustine hydrochloride. There are twenty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the bendamustine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bendamustine
A generic version of BENDAMUSTINE was approved as bendamustine hydrochloride by ACCORD HLTHCARE on December 7th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BENDAMUSTINE?
- What are the global sales for BENDAMUSTINE?
- What is Average Wholesale Price for BENDAMUSTINE?
Summary for BENDAMUSTINE
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 12 |
| Drug Prices: | Drug price information for BENDAMUSTINE |
| DailyMed Link: | BENDAMUSTINE at DailyMed |
US Patents and Regulatory Information for BENDAMUSTINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | POWDER;INTRAVENOUS | 205574-001 | Dec 7, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Avyxa Holdings | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 219014-001 | Jul 3, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dr Reddys | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | POWDER;INTRAVENOUS | 205376-001 | Dec 7, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Apotex | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | POWDER;INTRAVENOUS | 204230-002 | Jun 5, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Meitheal | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | POWDER;INTRAVENOUS | 211001-002 | Jun 5, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
